Mergers & Acquisitions ·
Zeo ScientifiX agrees to strategic partnership with Pluri Inc., issuing equity for exclusive US license
ZEOXZeo ScientifiX, Inc.
Zeo ScientifiX, Inc. entered into a definitive strategic agreement with Pluri Inc. to expand its U.S. manufacturing and commercialization platform in the regenerative medicine, aesthetics, wellness, and longevity markets. Under the terms of the partnership, ZEO will receive an exclusive license to Pluri’s proprietary 3D cell expansion technology for present and future products. In exchange, ZEO will issue shares resulting in Pluri holding a 41% equity stake at closing, with total ownership reaching 50% after additional share issuances and warrant exercises. The transaction includes the creation of Series D Non-Convertible Preferred Stock granting Pluri significant voting control and board representation. Closing is expected in the fourth quarter of 2026, subject to customary conditions. Zeo ScientifiX operates in the biotechnology sector, focusing on biologics manufacturing and commercialization.